#ESMO22: Trodelvy’s long-awaited survival data in breast cancer is finally in — and better than expected

It’s been weeks since Gilead touted “clinically meaningful” overall survival results from a second interim analysis of Trodelvy in a subset of metastatic breast cancer patients. Now we finally have a look at the hard data. Patients with HR+/HER2- metastatic breast cancer who received Trodelvy after prior endocrine therapy, CDK4/6…

…